Regel Therapeutics | Targeted GeneTherapy - Genetic disease - Haploinsufficiency - Targeted Therapeutic Technology - SCN2A -Biotechnology platform intended to revolutionize Gene Therapy
Combining cutting edge science, experienced business leaders and innovators, Regel Therapeutics is committed to leveraging its proprietary platform technology to revolutionize gene therapy and change patient outcomes across multiple indications.
Regel Therapeutics
Regel Therapeutics | Targeted GeneTherapy - Genetic disease - Haploinsufficiency - Targeted Therapeutic Technology - SCN2A -Biotechnology platform intended to revolutionize Gene Therapy/leaders is innovators, revolutionize its Combining science, to multiple patient edge gene across leveraging and proprietary experienced change cutting business platform Regel and indications. to outcomes technology therapy committed Therapeutics Regel Therapeutics | Targeted GeneTherapy - Genetic disease - Haploinsufficiency - Targeted Therapeutic Technology - SCN2A -Biotechnology platform intended to revolutionize Gene Therapy/leaders is innovators, revolutionize its Combining science, to multiple patient edge gene across leveraging and proprietary experienced change cutting business platform Regel and indications. to outcomes technology therapy committed Therapeutics Regel Therapeutics | Targeted GeneTherapy - Genetic disease - Haploinsufficiency - Targeted Therapeutic Technology - SCN2A -Biotechnology platform intended to revolutionize Gene Therapy/leaders is innovators, revolutionize its Combining science, to multiple patient edge gene across leveraging and proprietary experienced change cutting business platform Regel and indications. to outcomes technology therapy committed Therapeutics
